Abstract

Aim: This study compared the hyper volemic capacities of erythropoietin (Epo) and antioxidant drug U-74389G based on 2 preliminary studies. The provided results at mean corpuscular volumes (MCV) levels augmentation were co-evaluated in a hypoxia re oxygenation protocol of an animal model.

Materials and methods: MCV levels (MCVl) were evaluated at the 60th reoxygenation min (for groups A, C and E) and at the 120th reoxygenation min (for groups B, D and F) in 60 rats. Groups A and B received no drugs, rats from groups C and D were administered with Epo; whereas rats from groups E and F were administered with U-74389G.

Results: The first preliminary study of Epo non-significantly increased the MCVl by 0.30%+0.39% (p-value=0.4430). However, the second preliminary study of U-74389G significantly rised the MCVl by 1.60%+0.43% (p-value=0.0005). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has 4.352528-fold hypervolemic potency than Epo (p-value=0.0000).

Conclusion: The anti-oxidant capacities of U-74389G accelerate the acute hypervolemic properties; presenting 4.352528-fold rise on MCVl than epo (p-value=0.0000).

Keywords: Hypoxia; Erythropoietin; U-74389G; Mean corpuscular volume levels; Reoxygenation